纳武利尤单抗联合或不联合伊匹木单抗同步放化疗根治性治疗肌层浸润性膀胱癌的1期研究
这项多中心1b期开放标签剂量递增研究评估了同步放化疗联合三种免疫检查点抑制剂方案治疗非转移性肌层浸润性膀胱癌的安全性。结果显示纳武利尤单抗单药480 mg及纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg方案毒性可接受,而伊匹木单抗3 mg/kg联合纳武利尤单抗1 mg/kg方案因6例中3例出现剂量限制性毒性而终止。
要点
- 纳武利尤单抗480 mg同步放化疗组无剂量限制性毒性发生
- 纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg组2例出现剂量限制性毒性
- 伊匹木单抗3 mg/kg联合纳武利尤单抗1 mg/kg组6例中3例出现剂量限制性毒性而终止
核心结论
- 在这项同步放化疗联合免疫检查点抑制剂的剂量探索研究中,纳武利尤单抗单药方案和纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg方案毒性可接受。
研究设计与样本
- 多中心、1b期、开放标签、剂量递增研究,纳入26例非转移性(T2-4aN0-1)肌层浸润性膀胱癌患者。
- 患者接受丝裂霉素C/卡培他滨化疗及膀胱20次×2.75 Gy放疗。
- 耐受性在最多10例患者的队列中评估,若前6例中不超过2例或10例中不超过3例出现剂量限制性毒性,则继续纳入下一队列。
主要发现
- 纳武利尤单抗480 mg组无患者发生剂量限制性毒性。
- 纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg组2例患者发生剂量限制性毒性:血小板减少(4级)和心搏停止(5级)。
- 伊匹木单抗3 mg/kg联合纳武利尤单抗1 mg/kg组6例中3例发生剂量限制性毒性,该方案终止。
- ≥3级临床显著不良事件在纳武利尤单抗480 mg组、纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg组和伊匹木单抗3 mg/kg联合纳武利尤单抗1 mg/kg组分别发生于0例、3例和5例患者。
- 无转移生存率和总生存率在纳武利尤单抗480 mg组2年时为90%,在纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg组1年时为90%。
关键数值与推荐
- 纳武利尤单抗480 mg组:无剂量限制性毒性;≥3级不良事件0例。
- 纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg组:剂量限制性毒性2例(血小板减少4级、心搏停止5级);≥3级不良事件3例。
- 伊匹木单抗3 mg/kg联合纳武利尤单抗1 mg/kg组:剂量限制性毒性3例(6例中);≥3级不良事件5例。
- 无转移生存率和总生存率:纳武利尤单抗480 mg组2年时为90%;纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg组1年时为90%。
临床怎么用
- 作者报告纳武利尤单抗单药方案和纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg方案安全,可用于3期试验。
局限性
- 缺乏中心化的病理学和放射学审查。
- 缺乏生物标志物分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Muscle-invasive bladder cancer (MIBC) has a poor prognosis. Chemoradiotherapy (CRT) in selected patients has comparable results to radical cystectomy. Results of neoadjuvant immune checkpoint inhibitors (ICIs) before radical cystectomy are promising. We hypothesize that ICI concurrent to CRT (iCRT) is safe and may improve treatment outcomes. OBJECTIVE: To determine the safety of iCRT for MIBC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, phase 1b, open-label, dose-escalation study determined the safety of CRT with three ICI regimens in patients with nonmetastatic (T2-4aN0-1) MIBC. Twenty-six patients received mitomycin C/capecitabine and 20 × 2.75 Gy to the bladder. Tolerability was evaluated in a cohort of up to ten patients. If two or fewer out of the first six patients or three or fewer of ten patients experienced dose-limiting toxicity (DLT), accrual continued in the next cohort. INTERVENTION: Patients received nivolumab 480 mg (NIVO480), nivolumab 3 mg/kg and ipilimumab 1 mg/kg (NIVO3 + IPI1), or nivolumab 1 mg/kg and ipilimumab 3 mg/kg (IPI3 + NIVO1). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was safety. Secondary objectives were response rate, disease-free survival, metastatic-free survival (MFS), and overall survival (OS). RESULTS AND LIMITATIONS: In the NIVO480 cohort, no patients experienced DLT. The NIVO3 + IPI1 2 patients experienced DLT, thrombocytopenia (grade 4), and asystole (grade 5). IPI3 + NIVO1 was discontinued after three out of six patients experienced DLT. Clinically significant adverse events (AEs) of grade ≥3 occurred in zero, three, and five patients in the NIVO480, NIVO3 + IPI1, and IPI3 + NIVO1 groups, respectively. The most common AEs were immune related and gastrointestinal. MFS and OS were 90% at 2 yr for NIVO480 and 90% at 1 yr for NIVO3 + IPI1. Limitations include the absence of a centralized pathology and radiology review, and a lack of biomarker analysis. CONCLUSIONS: In this dose-finding study of iCRT, the regimens of nivolumab monotherapy and nivolumab 3 mg/kg with ipilimumab 1 mg/kg have acceptable toxicity. PATIENT SUMMARY: We tested the safety of a new bladder-sparing treatment modality for muscle-invasive bladder cancer patients, combining immune checkpoint inhibitors simultaneously with chemoradiotherapy. We report that two regimens, nivolumab monotherapy and nivolumab 3 mg/kg with ipilimumab 1 mg/kg, are safe and can be used in phase 3 trials.
引用
- de Ruiter BM, van Hattum JW, Lipman D, et al. Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer. Eur Urol. 2022. PMID: 35933242. doi:10.1016/j.eururo.2022.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。